Kura Oncology completes first U.S. commercial sale of KOMZIFTI, triggering $135M milestone payment from Kyowa Kirin

Kura Oncology, Inc.

First commercial sale of KOMZIFTI (ziftomenib) completed on December 2, 2025.
Milestone triggers $135M payment from Kyowa Kirin, expected before year-end 2025.
KOMZIFTI received FDA approval on November 13, 2025.
Payment is under the existing collaboration and license agreement with Kyowa Kirin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.